Biotech

Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment

TUSTIN, CA: UTSW Collaborators Found Phosphatidylserine (PS)-Targeting Antibody in Combination With an Anti-PD-1 or an Anti-CTLA-4 Immune Checkpoint Inhibitor Promotes a Robust, and Localized Anti-Tumor Response ...

Atossa Genetics to Present at the 13th Annual BIO Investor Forum October 8, 2014

SEATTLE, WA: ...

iBio Reports on Filing of 2014 Annual Report

NEWARK, DE: ...

Critical Outcome''s Lead Cancer Drug Candidate, COTI-2, Receives Sixth U.S. Patent and First Japanese Patent

LONDON, ONTARIO: Additional Patents Further Enhance the Value of COTI-2 ...

ViroCyt and I&L Biosystems Launch Virus Counter(R) 3100 at the World Vaccine Congress in Brussels

BOULDER, CO: ...

Quest PharmaTech Signs License Agreement With Bioceltran Co., Ltd. for Photodynamic Therapy Technology

EDMONTON, ALBERTA: ...

RepliCel to Present Clinical Trial Update at Stem Cell Meeting on the Mesa Partnering Forum in California

VANCOUVER, BRITISH COLUMBIA: ...

Prima BioMed Announces Strategic Acquisition of Immutep SA

SYDNEY, AUSTRALIA: ...

Boston Therapeutics Appoints Jan Brinkman, M.D., Ph.D. and Alan M. Hoberman, Ph.D. to Board of Directors

MANCHESTER, NH: Increases Total Number of Board Members to Eight ...

Immunovaccine Announces Plans for Phase II Clinical Trial of DPX-Survivac in Patients with Recurrent Lymphoma

HALIFAX, NOVA SCOTIA: Novel Cancer Vaccine to Be Studied in Combination with Immune Modulating Agent ...